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These guidelines do not establish a standard of care to be followed in every case. It is
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on the circumstances existing at the time. It is impossible to anticipate all possible situations
that may exist and to prepare guidelines for each. Accordingly, these guidelines should guide
care with the understanding that departures from them may be required at times.
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Definition: Asthma is a chronic inflammatory disorder of the airways characterized by recurrent and
reversible airflow obstruction. Airways swell, and produce extra mucous in addition to bronchospasm,
resulting in overall narrowing of the airway. Increased coughing, wheezing, and shortness of breath are
typical symptoms. In the United States, more than 6 million children are affected with asthma (CDC,
2014) and in 2010, there were 439,000 hospital discharges with asthma listed as the first diagnosis
(Bloom, Cohen, & Freeman, 2012).
Objective of Guideline: The objective of this guideline is to standardize the care of children seen on
the inpatient units for asthma.
Target Users: Providers, staff nurses, and respiratory therapists caring for children with asthma on the
inpatient units.
Guideline Inclusion Criteria: Children greater than or equal to 2 years of age and less than 18 years
of age with symptoms consistent with asthma exacerbation, including difficulty breathing, coughing, and
wheezing.
Guideline Exclusion Criteria:
 Children greater than 2 years of age admitted with first-time wheezing secondary to a known
infection. Children with the following underlying conditions:
Severe gastroesophageal reflux
Cystic fibrosis
HIV with possible Pneumocystis pneumonia (PJP)
Immunodeficiency
History of chronic aspiration
Bronchopulmonary dysplasia
Tracheomalacia
History of lower airway surgery
Congenital heart disease
Differential Diagnosis: (in alphabetical order)
Aspiration
Bacterial pneumonia
Bronchiolitis
Croup
Congestive heart disease
Foreign body
Inhalation injury
Clinical Questions Posed by the Guideline:
1. What level of oxygen saturation was used as a cutoff for initiation of supplemental oxygen for
subjects in studies of asthma exacerbations?
2. What are the maximum doses of continuous albuterol?
3. In the child hospitalized with an asthma exacerbation, should intravenous fluids be routinely
administered?
4. In the child hospitalized with an asthma exacerbation, should intravenous magnesium sulfate be used
to improve pulmonary function?
5. In the child hospitalized with an asthma exacerbation, should more than one treatment with
intravenous magnesium be given?
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6. In the child hospitalized with an asthma exacerbation, should albuterol be administered by nebulizer
or metered-dose inhaler (MDI) and spacer to improve pulmonary function?
7. In the child hospitalized with an asthma exacerbation, should
methylprednisolone/prednisolone/prednisone vs. dexamethasone be used to improve pulmonary
function?
8. In the child hospitalized with an asthma exacerbation, should inhaled steroids be initiated during an
asthma exacerbation to improve pulmonary function or should inhaled corticosteroids be continued if
the treatment is included on the child’s home Asthma Action Plan?
9. In the child hospitalized with an asthma exacerbation, should positive expiratory pressure (PEP)
therapy be used?
10. For the child who has had > or = to four ED/UCC/inpatient episodes in the last 12 months (including
the current visit), what is the efficacy of consulting:
o Allergy, Asthma, Immunology OR Pulmonary Medicine?
o Social Services?
o Environmental Health?
Practice Recommendations (EPR-3, 2007):
Inpatient asthma care is either:
The initiation of care for an exacerbation or the continuation of care received in the emergency
department (ED) or other medical care setting. The following treatments are recommended for inpatients
with asthma exacerbations:
1. Supplemental oxygen should be administered to maintain a SpO2 greater to or equal to 90-92%,
unless otherwise directed.
2. Bronchodilators (for all patients) should be given.
3. Continue home controller medication, or consider starting an inhaled corticosteroid. We do not
recommend treating an asthma exacerbation with inhaled corticosteroids ONLY.
4. Systemic corticosteroids (for most patients) should be given.
The dose and frequency of the three principal treatments (supplemental oxygen, albuterol, and systemic
corticosteroids) are determined by the severity of the exacerbation.
The following adjunctive therapies may be helpful:
1. Intravenous magnesium
2. Positive Expiratory Pressure (PEP)
The administration of the following treatments is NOT recommended (in alphabetical order):
3.
4.
5.
6.
7.
8.

Aggressive hydration
Antibiotics (except as needed for concurrent infections or other conditions)
Chest physiotherapy
Methylxanthines
Mucolytics
Sedation

Physical Exam: Obtain vital signs, including SpO2. The physical exam of the respiratory system should
include assessment of aeration throughout the lung fields, auscultation for wheezing, and the observation
for the presence of increased work of breathing (accessory muscle use and retractions). Neurologic signs
such as altered mental status, agitation, or drowsiness should be included in the exam. Cardiovascular
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signs such as significant tachycardia and hypotension should be monitored closely, especially if
continuous albuterol or magnesium was or will be given.
Diagnostics: Diagnostic testing, in general, is typically not necessary and should only be performed
based on the clinical presentation of each patient. When diagnostic studies are deemed necessary,
performing these tests should not hinder the treatment of the asthma exacerbation; they should occur
simultaneously so as not to delay treatment. Chest x-rays do not have to be routinely obtained on all
patients with asthma exacerbations. Peak flow and spirometry can provide useful information about the
severity of obstruction a patient has; however, not all patients are able to adequately perform this testing
in the midst of an acute exacerbation. An ABG can be obtained if there is concern that a patient is not
adequately ventilating or oxygenating and is progressing toward respiratory failure. Usually, though,
ABGs are not needed in the initial evaluation of a patient with an asthma exacerbation (EPR-3, 2007).
Respiratory Care Score (RCS): Utilizing information from the patient’s history and physical exam, an
RCS can be calculated. Multiple RCSs have been developed and studied in order to determine the severity
of a patient’s asthma exacerbation, predict hospital admission, and response to therapy. Various unvalidated scoring systems have been developed and utilized by individual facilities to monitor response
and to help guide therapy. Children’s Mercy developed a tool that incorporates patient history and
physical exam findings into a score, the RCS, which is incorporated into an overall Respiratory Care Plan
(RCP).
Treatment:
 Continue or initiate supplemental oxygen to maintain a SpO2 ≥ 90-92%.
 Continue or initiate beta agonists (Mild/Moderate Asthma via MDI or Moderate/Severe Asthma via
continuous nebulizer).
 Initiate or continue treatment with a systemic corticosteroid.
 Consider continuation of inhaled corticosteroids (if the patient uses inhaled corticosteroids at home)
or initiation of inhaled corticosteroids.
 Consider treatment with intravenous magnesium sulfate, if the patient has not received this
treatment.
 Consider PEP therapy, per the Respiratory Care Plan.
Discharge:
Prior to discharge the following tasks should be completed:
 Develop or adjust an Asthma Action Plan (AAP) for each patient.
 Provide education to each patient and parent(s)/guardian(s) about asthma, the medications used to
treat asthma, the patient’s AAP, and risk factors to avoid.
 Provide environmental health information and/or an environmental health assessment if a patient’s
history suggests that the patient’s living environment significantly contributes to his/her asthma
symptoms.
 Arrange for follow-up with the patient’s Primary Care Provider (PCP) and/or with an Asthma
Specialist.
 During the influenza season, offer the influenza vaccine prior to discharge if the patient has not
received the annual influenza vaccine and has no specific contraindications to receiving it.
Measures:
Outcome measures:

Three measures reported to Joint Commission
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o Asthma Action Plan developed prior to discharge
o Length of Stay
Potential process measures:
o Use of Asthma Inpatient CPG Power Plan
Balancing measure(s):
o Rate of hospital asthma readmission within 7 days
o Adverse effects of IV magnesium sulfate for inpatients
Potential Cost Implications:

Potentially decrease RT utilization as time to deliver albuterol by MDI spacer is less than by nebulizer

Increase in assessment of proper MDI usage and targeted education on MDI/spacer technique
resulting in:
o Potential decrease in readmission because home administration of medication is more efficacious
o Potential decrease in Emergency Department visits/readmissions because patients go home with
an albuterol MDI/spacer that bridges the gap in the time between discharge and obtaining their
albuterol prescription filled at their pharmacy
Potential Organizational Barriers:

Reluctance of providers and Respiratory Therapists to change practice from the use of nebulizers
(intermittent) to the use of MDI/spacer in the hospital setting

Change in pharmacy practice/costs to obtain more MDIs and spacers and dispose of inhalers
(regulations recently changed disposal to black diamond boxes) versus nebulizers which are
disposed in regular trash
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Clinical Questions Answered:
Question 1: What level of oxygen saturation was used as a cutoff for initiation of
supplemental oxygen for subjects in studies of asthma exacerbations?
Inpatient asthma team recommendation:
Based on moderate quality evidence, the inpatient asthma team strongly recommends using
supplemental oxygen to keep the patient’s oxygen saturation ≥ 90-92%. Pulse oximetry measurements
are used to assess the severity of the exacerbation and the response to treatment. In infants and
children, where the ability to perform FEV1 or PEF testing is diminished, monitoring SpO2 is essential.
SpO2 less than 90-92% on room air is an indicator for hospitalization, therefore the goal is to keep SpO2
greater than or equal to 90-92% (EPR-3, 2007). The benefits of an oxygen saturation ≥ 90-92%
outweigh undesirable effects. This recommendation applies to most patients in most circumstances.
Further research (if performed) is likely to have an important effect on our confidence in the estimate of
effect and may change the estimate.
Literature (see Appendix A) supporting this recommendation:
The literature since (EPR-3, 2007) was searched and no new research was found. Boychuk, Yamamoto,
DeMesa, & Kiyabu (2006) was referenced to support EPR-3 (2007) (See Table 1). Colorado Children’s
Guideline (2011) states supplemental oxygen should be used for any child whose SpO2 is less than 90%
and Cardinal Glennon’s Guideline (2009) does not give guidance on this recommendation. Ten citations
were read to establish the oxygen saturation level utilized to determine therapy (see Table 2).
Search strategy implemented:

PubMed performed February 26 2015:( There were no new citations that addressed the question since
the 2010 search was performed).

("Asthma"[Mesh] AND ("Emergency Service, Hospital"[Mesh] OR "Emergency Nursing"[Mesh] OR
"Emergency Medical Services"[Mesh] OR "Emergency Medicine"[Mesh] OR "Acute Disease"[Mesh] OR
exacerbation[All Fields] OR attack[All Fields])) AND ("Oximetry"[Mesh] OR "permissive hypoxia"[All
Fields]) AND ((Meta-Analysis[ptyp] OR Practice Guideline[ptyp] OR Randomized Controlled Trial[ptyp]
OR Guideline[ptyp]) OR ("Cohort Studies"[Mesh] OR "Epidemiologic Studies"[Mesh] OR
systematic[sb])) AND English[lang] AND ("infant"[MeSH Terms] OR "child"[MeSH Terms] OR
"adolescent"[MeSH Terms])http://www.ncbi.nlm.nih.gov/sites/myncbi/collections/public/10Wv9ymwCX6RXeY07Yk-EXQz/
19 citations

CINAHL performed Sept 16, 2010:

S1 (MH "Acute Disease") Limiters - Exclude MEDLINE records Search modes - Boolean/Phrase
S2 (MH "Emergency Medical Services+") OR (MH "Emergency Service+") OR (MH "Emergency
Nursing+") OR (MH "Emergency Medicine") Limiters - Exclude MEDLINE records Search modes Boolean/Phrase. No citations
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Table 1

Synthesis of relevant literature about oxygen saturation values to guide treatment of children with acute asthma exacerbations
Author, date,
country, and
industry of
funding
(Boychuk et
al., 2006).

Patient Group
1219
encounters of
1008 unique
children with
acute asthma
in 5
EDs/clinics,
including
urban,
suburban,
and rural
settings.
Children were>
12 months
and < 18
years,
presenting
with wheezing
or
bronchospas
m.
Convenience
enrollment

Level of
Evidence

Research
design

Low

Prospective
cohort study.
Asthma
severity was
determined
by NIH
severity class
groups.
Phase 1
subjects
received
usual care.
Phase 2
subjects
received an
educational
video, and a
written
asthma action
plan

Significant results

Limitations

Phase 1 and Phase 2 groups were similar except
Phase 2 subjects were older. (Phase 1 mean
age was 3.6 + 2.3 and Phase 2 mean age was
4.3 + 3.4 [p< 0.0001]).
The overall hospitalization rate was 15%.
The greater the severity classification, the higher
the hospitalization rate.
The lowest severity group was least likely to
have an asthma action plan.
Hospitalization rates by presenting oxygen
saturation:
Presenting oxygen
Admission rate
saturation
98% -100%
6%
95%-97%
12%
93%-94%
28%
90%-92%
45%
85%-89%
65%
80%-84%
100%
The mean O2 saturation across severity scores
ranged from 96.0 +3.0 to 96.8+2.5. There was
no significance among initial O2 saturation and
severity score. Severity score was not related to
admission rate.

Severity Score is a global
score of asthma, not a
measure of the event that
brought the child to the ED.
It is easy to confuse the
term “severity score” in
relation to the acute event
versus the burden of the
disease which the score
measures.
The age difference between
Phase 1 and Phase 2
subjects could be a concern
for bias.
Some of the initial O2
saturation measures may
have been obtained with
the subject receiving
supplemental O2.
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Table 2

Oxygen saturation level used to determine need for oxygen therapy in ten research papers and altitude of study location
Saturated oxygen values

Locations altitudes

(Kelly, Kerr, & Powell,
2004)

Mild > 94%, Moderate 94-90% and Severe < 90%

36 Australian centers various
altitudes
Toronto Canada, altitude:
105 m. (347 ft.)

(Keogh et al., 2001)

Used a saturated oxygen of < 92% to administer supplemental oxygen

(Sole, Komatsu,
Carvalho, & Naspitz,
1999)

92% was the cut off predicting the necessity to repeat treatment

Sao Paulo Brazil, altitude:
637 ft.

(Wright, Santucci, Jay, &
Steele, 1997)

Pretreatment saturated oxygen < 91% was not useful in predicting
admission/relapse (sensitivity 0.24, specificity 0.86, likelihood ratio of 1.77) and
Post treatment saturated oxygen < 91% had a sensitivity of 0.34 and a specificity
of 0.98 with a likelihood ratio of 16.43 to predict admission/relapse.

Providence RI, altitude: 50
ft.

(Keahey et al., 2002)

The mean saturated oxygen of children admitted was 93 + 5% and the mean
saturated oxygen of children not admitted was 96% + 3%

(Carruthers & Harrison,
1995)

Adults 32% were smokers

(Mehta, Parkin,
Stephens, Keogh, &
Schuh, 2004)

In the group (n= 107) that needed < 4 hours of frequent bronchodilator treatment
(FBT) presenting saturated oxygen was 95.5 + 2. In the group (n=166) that
needed > 4 hours of FBT, presenting saturated oxygen was 93.3 + 3.8

Toronto Canada, altitude:
105 m. (347 ft.)

(Boychuk et al., 2006)

Presenting saturated oxygen < 90 related to increased hospitalization

Honolulu, HI, altitude: 4 m.
(9 ft.)

44 Emergencies 18 in US
states and 4 Canadian
provinces. Various altitudes
Norwich UK, altitude: 30 m.
(28 ft.)
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First Author, Year

(Connett & Lenney,
1993)

(Geelhoed, Landau, &
LeSouef, 1994)

Saturated oxygen values

Locations altitudes

Inpatients 75, all were children. All children required nebulization therapy with
salbutamol 5 mg. Only those who required hospitalization were included in the
study. Oxygen saturation was measured prior to nebulization and 10 minutes post
nebulization. Children were awake. All received prednisone 2 mg/kg, PO. A post
nebulization oxygen saturation that was < 91% best predicted the need for IV
treatment (IV aminophylline and hydrocortisone).

Brighton, UK altitude: 0 ft.

Subjects: 280 children who were enrolled when the primary investigator was
working. 198 were receiving episodic treatment and 82 were receiving regular
treatment, including 11 who were on regular oral steroids. Treated in the ED with
nebulized salbutamol. A minority (n = unknown) were given oral steroids.
Subjects with a poor outcome (admission to the hospital) had a mean oxygen
saturation of 92.4%, SD 3.2%. Subjects with a good outcome (discharged from
the ED) had a mean oxygen saturation of 95 %, SD 2.0%.

Perth, Western Australia
altitude: 66 ft.
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Question 2: What are the maximum doses of continuous albuterol?
Inpatient asthma team recommendation:
EPR-3 (2007) recommends the following dosages for intermittent and continuous albuterol:
 Child dose (≤ 12 years of age)—0.15 mg/kg (minimum dose 2.5 mg) every 20 minutes for 3
doses then 0.15 to 0.3 mg/kg up to 10 mg every 1 to 4 hours as needed, or 0.5 mg/kg/hour by
continuous nebulization with a maximum of 10 mg/hour continuously.
 Adult dose (> 12 years of age)—2.5 to 5 mg every 20 minutes for 3 doses, then 2.5 to10 mg
every 1 to 4 hours as needed, or 10 to 15 mg/hour continuously.
EPR-3 (2007) recommends only selective beta2-agonists (albuterol, levalbuterol, pirbuterol). For optimal
delivery, dilute aerosols to minimum of 3 mL at gas flow of 6–8 L/min. Use large volume nebulizers for
continuous albuterol administration. The inpatient asthma team concurs with these recommendations,
including the use of 15 mg/hour as the maximum dose per hour of continuous albuterol. The inpatient
asthma team values amelioration of symptoms while minimizing adverse effects of the medication. This is
a strong recommendation based on high quality evidence (EPR-3, 2007).
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Question 3: In the child hospitalized with an asthma exacerbation, should intravenous fluids
be routinely administered?
Inpatient asthma team recommendation:
EPR-3 (2007) does not recommend routine intravenous fluids for older children with asthma. The
assessment of the hydration status of patients will guide the decision to start intravenous fluids. In young
children, an increased respiratory rate coupled with decreased oral intake, may put the child at risk for
dehydration.
Literature (Appendix B) supporting this recommendation:
An extensive literature search was performed and was not successful in finding information to answer this
specific question.
Search strategy implemented:
PubMed search performed December 20 2011, and repeated February 26 2015, no new citations were
identified.
"asthma"[All Fields] AND ("Fluid Therapy"[Mesh] OR "Infusions, Parenteral"[Mesh] OR "Saline Solution,
Hypertonic"[Mesh] OR "Hypotonic Solutions"[Mesh] OR "Isotonic Solutions"[Mesh] OR "Water-Electrolyte
Balance"[Mesh] OR "Water-Electrolyte Imbalance"[Mesh] OR "Rehydration Solutions"[Mesh]) AND
((Meta-Analysis[ptyp] OR Practice Guideline[ptyp] OR Randomized Controlled Trial[ptyp] OR
Guideline[ptyp] OR "Comparative Study"[Publication Type] OR "Controlled Clinical Trial"[ptyp]) OR
("Cohort Studies"[Mesh] OR systematic[sb])) NOT (Editorial[ptyp] OR Letter[ptyp] OR Comment[ptyp]
OR Case Reports[ptyp]) AND English[lang] AND ("infant"[MeSH Terms] OR "child"[MeSH Terms] OR
"adolescent"[MeSH Terms]) AND ("2001/12/31"[PDat] : "2011/12/28"[PDat])
34 citations
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Question 4: In the child hospitalized with an asthma exacerbation, should intravenous
magnesium sulfate be used to improve pulmonary function?
Question 5: In the child hospitalized with an asthma exacerbation, should more than one
treatment with intravenous magnesium be given?
Inpatient asthma team recommendation:
Based on very low quality evidence, the inpatient asthma team recommends the consideration of IV
magnesium sulfate for children hospitalized for a severe asthma exacerbation if conventional therapy is
failing and it has not been already given.
Based on very low quality evidence we recommend considering the administration of intravenous
magnesium for children with moderate asthma exacerbations that have failed to respond to continued
therapy after one hour. Research performed in adults has shown beneficial effects of magnesium given to
adult patients seen in the Emergency Department for asthma exacerbations.
Additionally, no literature was found to answer the question about providing more than one dose of
magnesium sulfate. We cannot recommend for or against multiple doses of magnesium when treating
hospitalized patients with asthma exacerbations. We place a high value on using therapies with known
efficacies. Further research (if performed) is likely to have an important effect on our recommendation.
Literature (Appendix C):
No literature was found regarding the use of IV magnesium in children hospitalized for asthma
exacerbations. However, for adult patients seen in the Emergency Department, administration of
intravenous magnesium has been shown to significantly improve respiratory function as measured by
PEFR (% predicted) and asthma score. SMD 1.94, 985% CI [0.8, 3.08] (Mohammed & Goodacre, 2007).
This evidence is graded as very low quality based on three factors.
1. The evidence does not directly apply to hospitalized children; all studies were completed in the
ED.
2. The findings are imprecise. The number of subjects in the in the meta- analysis is 128 total
subjects.
3. The outcome PEFR is difficult to measure in children < 5 years. It is unknown if the children were
able to adequately perform the maneuver to obtain this outcome.
Torres et al. (2012) reported a significant reduction in use of mechanical ventilation when IV magnesium
sulfate (25 mg/kg, maximum 2 grams over 20 minutes) was administered to children aged 2-15 years
within the first hour of presentation of a severe asthma attack (Wood’s score >/= 5) (See Figure 1).
We did not find any evidence to support or refute more than one treatment with IV magnesium sulfate.
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Forest Plot comparison
IV Magnesium
Study or Subgroup

Events

Torres 2012

Total Events Total Weight

4

22

76

Total (95% CI)
Total events

76

4

0.16 [0.06, 0.44]

67 100.0%

0.16 [0.06, 0.44]

A B C D E F G

M-H, Fixed, 95% CI

M-H, Fixed, 95% CI

67 100.0%

Risk of Bias

Risk Ratio

Risk Ratio

Control

+ + – + + + ?

22

Heterogeneity: Not applicable
Test for overall effect: Z = 3.54 (P = 0.0004)

0.01

0.1

1

10

100

IV Magnesium Control

Risk of bias legend
(A) Random sequence generation (selection bias)
(B) Allocation concealment (selection bias)

(C) Blinding of participants and personnel (performance bias)
(D) Blinding of outcome assessment (detection bias)
(E) Incomplete outcome data (attrition bias)
(F) Selective reporting (reporting bias)
(G) Other bias

Figure 1. Intravenous magnesium sulfate vs. control in Severe Asthma, Outcome: Need for mechanical ventilation
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Question 6: In the child hospitalized with an asthma exacerbation, should albuterol be
administered by nebulizer or metered-dose inhaler (MDI) and spacer to improve pulmonary
function?
Inpatient asthma team recommendation:
EPR-3 (2007) makes no statement of preference of using a nebulizer over an MDI with a valved spacer
for the administration of inhaled medications. In addition, they conclude “it is important to assess inhaler
techniques for all prescribed medications and reinforce correct technique before patients are discharged
home.” Thus, based on studies conducted in Emergency Departments for children with mild-to-moderate
exacerbations, administration of inhaled medications via an MDI plus valved holding chamber is as
effective as nebulized therapy with appropriate administration technique and coaching by trained
personnel. A mask should be used for children < 4 years of age. Nebulized albuterol should be reserved
for children with moderate-to-severe symptoms. We placed high value on prompt resolution of symptoms
and the ability to evaluate the patient’s technique when using an MDI and spacer.
Literature:
Literature was not found to support using MDI with spacer versus nebulizer for the delivery of albuterol
for children hospitalized with asthma exacerbation.
Search strategy:
(("Asthma"[Mesh] AND ("Emergency Service, Hospital"[Mesh] OR "Emergency Nursing"[Mesh] OR
"Emergency Medical Services"[Mesh] OR "Emergency Medicine"[Mesh] OR "Acute Disease"[Mesh] OR
exacerbation[All Fields] OR attack[All Fields])) AND ("Magnesium Sulfate"[Mesh]
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Question 7: In the child hospitalized with an asthma exacerbation, should
methylprednisolone/ prednisolone/prednisone vs. dexamethasone be used to improve
pulmonary function?
Inpatient asthma team recommendation:
Based on high quality evidence, we recommend a 5-day course of oral prednisolone/prednisone for acute
asthma exacerbations. The National guideline (EPR-3, 2007) states dexamethasone is not preferred due
to the increased duration of drug activity that increases the risk of adrenal suppression. For this
recommendation, we placed a high value on decreasing unscheduled re-evaluations, re- admissions, and
cost of treatment.
Literature (see Appendix D) supporting this recommendation:
Since EPR-3 (2007) a meta- analysis of six studies by Keeney et al. (2014) reported that relapse rate at 5
days and 10-14 days post treatment for asthma exacerbation were similar for children treated with
dexamethasone or prednisolone/prednisone. The forest plots of the studies included in Keeney are
included in Figures 2 and 4. In addition, they reported that vomiting was significantly less in the groups
treated with dexamethasone. GRADing the Keeney et al., (2014) paper shows the following (see Tables 3
and Table 4).
For the vomiting comparison, treatment with dexamethasone was intramuscular in three of the four
studies, while treatment with prednisolone/prednisone was PO in all studies. Prednisolone/prednisone
doses were either singular or multiple oral doses
1. Doses of corticosteroids varied widely across studies:
o The dose of IM dexamethasone ranged from 0.3 mg/kg with a mix of 15 mg IM X 1 dose to
1.7 mg/kg (max 36 mg) IM X 1 dose. The range of oral dexamethasone ranged from 0.3
mg/kg (max 15 mg) PO X 1 dose to 0.6 mg/kg (max 16 mg) PO once daily X 2 days.
2. The studies were not powered on the outcome vomiting.
Therefore, the asthma inpatient team does not recommend the use of dexamethasone over
prednisolone/prednisone at this time. Future research will change our confidence in the estimate of the
effect.

15

16
October 2016
Tables
TABLE 3

GRADE assessment of studies included in (Keeney et al., 2014).
Quality assessment

No of
studies

Design

No of patients

Effect

Relative
Risk of
InIndirectOther
Imprecision
Dexamethasone Prednisone (95% Absolute
bias consistency
ness
considerations
CI)

Quality Importance

Vomiting in the ED (follow-up 2-4 hours)
4

randomized serious1,2 serious3,4
trials

no serious serious5
indirectness

none

6/506
(1.2%)

27/511
(5.3%)

OR 0.18 43 fewer per
(0.07 to 1000 (from VERY
0.45) 27 fewer to LOW
49 fewer)

CRITICAL

Relapse rate - 5 days (follow-up 5 days; assessed with: number who returned for treatment of the exacerbation)
4

randomized serious1,2 serious3,4
trials

no serious serious5
indirectness

none

14/167
(8.4%)

15/169
(8.9%)

OR 0.96 3 fewer per
(0.43 to 1000 (from
2.11) 49 fewer to
82 more)

CRITICAL
VERY
LOW

Relapse rate - 10-15 days (follow-up 10-14 days; assessed with: number who returned for treatment of exacerbation)
3

randomized serious1,2 serious3,4
trials

no serious serious5
indirectness

none

47/391
(12%)

40/372
(10.8%)

OR 1.18 17 more per
(0.74 to 1000 (from
1.87) 26 fewer to
76 more)

CRITICAL
VERY
LOW
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1

There is poor reporting of allocation concealment in half of the studies.
One third of the studies blinded the participants, and in only one study were outcome assessors blinded.
3
The I2 statistic low (0- 18.7) but there were differences in the treatments, 3 studies used a single IM dose of dexamethasone, 1 study used a single oral dose
and 2 studies used multiple oral doses.
4
The dose of IM dexamethasone ranged from 0.3 mg/kg with a maximum of 15 mg IM X 1 dose to 1.7 mg/kg 1.7 mg/kg (max 36 mg) IM X 1 dose. The range of
oral dexamethasone ranged from 0.3 mg/kg (max 15 mg) PO X 1 dose to 0.6 mg/kg (max 16 mg) PO once daily X 2 days.
5
Low number of subjects and low number of events
2

Table 4

Dose and duration of Intervention and Comparison of the studies included in Keeney et al., (2014)
Author
Single IM dose
(Gries, Moffitt, Pulos, &
Carter, 2000)
(Gordon, Tompkins, &
Dayan, 2007)
(Klig, Hodge, &
Rutherford, 1997)
Single Oral Dose
(Altamimi et al., 2006)
Multiple Oral Dose
(Greenberg, Kerby, &
Roosevelt, 2008)
(Qureshi, Zaritsky, &
Poirier, 2001)

Intervention
Dexamethasone 1.7 mg/kg (max 36 mg) IM X 1 dose
Dexamethasone 0.6 mg/kg (max 15 mg) IM X 1 dose

Comparison
Prednisone or prednisolone 1 mg/kg (max 20 mg) PO twice
daily X 5 days
Prednisolone 2 mg/kg (max 50 mg) PO daily X 5 days

Dexamethasone 0.3 mg/kg (max 15 mg) IM X 1 dose

Prednisone 2 mg/kg (max 100 mg) PO X 1 dose, then 1 mg/kg
PO daily X 2 days

Dexamethasone 0.6 mg/kg (max 18 mg) PO X 1 dose, then
placebo PO twice daily for 5 days

Prednisone or prednisolone 1 mg/kg (max 30 mg) PO X 1
dose, then 1 mg/kg PO twice daily X 5 days

Dexamethasone 0.6 mg/kg (max 16 mg) PO once daily X 2
days
Dexamethasone 0.6 mg/kg (max 16 mg) PO once daily X 2
days

Prednisone 2 mg/kg (max 80 mg) PO X 1 dose, then 1
mg/kg(max 30 mg) PO twice daily X 4 days
Prednisone or prednisolone 2 mg/kg (max 60 mg) PO X 1
dose, then 1 mg/kg (max 60 mg) PO daily X 4 days
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Figures
Dexamethasone
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Odds Ratio
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M-H, Fixed, 95% CI
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3.86 [0.42, 35.62]

Gordon 2002

25.4%

0.71 [0.29, 1.74]
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69

14

73

Gries 2000

0

15

0

18

Klig 1997

0

22

0

Subtotal (95% CI)
Total events

167
14

Not estimable

22

Not estimable

169

27.6%

0.96 [0.43, 2.11]
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Heterogeneity: Chi² = 1.93, df = 1 (P = 0.16); I² = 48%

Test for overall effect: Z = 0.11 (P = 0.91)
1.5.2 10-15 days
Gordon 2002
Greenburg 2008

Qureshi 2001

19

68

19

73

28.9%

1.10 [0.52, 2.32]

8

51

3

38

6.3%

2.17 [0.54, 8.80]

272

18

261

37.2%

1.07 [0.55, 2.07]

372

72.4%

1.18 [0.74, 1.87]

20

Subtotal (95% CI)

Total events

391

47

40

Heterogeneity: Chi² = 0.84, df = 2 (P = 0.66); I² = 0%

Test for overall effect: Z = 0.70 (P = 0.48)
1.5.3 30 days

Gries 2000

0

Subtotal (95% CI)

Total events

15

0

15

0

18

Not estimable

18

Not estimable

0

Heterogeneity: Not applicable
Test for overall effect: Not applicable
Total (95% CI)

Total events

573

61

559 100.0%

1.12 [0.75, 1.67]

55

Heterogeneity: Chi² = 3.05, df = 4 (P = 0.55); I² = 0%

Test for overall effect: Z = 0.55 (P = 0.58)

0.01

0.1

1

Dexamethasone

10

100

Prednisone/Predisolone

Test for subgroup differences: Chi² = 0.20, df = 1 (P = 0.65), I² = 0%

Figure 2. Dexamethasone vs. Prednisone/prednisolone, Outcome Relapse. All studies except Gordon et al.
(2007) compare administration by mouth. Gordon et al. (2007) compared dexamethasone
intramuscularly vs. prednisone/prednisolone by mouth.
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Dexamethasone
Study or Subgroup

Events

Prednisone

Total Events

Odds Ratio

Total Weight

Altamini 2006

0

57

0

61

Gordon 2002

0

89

9

93

33.9%

0.05 [0.00, 0.87]

Greenburg 2008

5

51

7

38

26.5%

0.48 [0.14, 1.65]

Qureshi 2001

1

309

11

319

39.6%

0.09 [0.01, 0.71]

511 100.0%

0.18 [0.07, 0.45]

Total (95% CI)

Total events

506

6

Odds Ratio

M-H, Fixed, 95% CI

M-H, Fixed, 95% CI

Not estimable

27

Heterogeneity: Chi² = 3.63, df = 2 (P = 0.16); I² = 45%

0.01

Test for overall effect: Z = 3.64 (P = 0.0003)

0.1

1

Dexamethasone

10

100

Prednisone/Predisolone

Figure 3. Dexamethasone vs. Prednisone/Prednisolone, Outcome Vomiting in the ED. All studies except

Gordon et al., (2007) compare administration by mouth. Gordon et al., (2007) compared dexamethasone
intramuscularly vs. prednisone/prednisolone by mouth.
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Events

Prednisone

Total Events

Odds Ratio

Total Weight

Altamini 2006

0

57

0

61

Greenburg 2008

5

51

7

38

40.1%

0.48 [0.14, 1.65]

Qureshi 2001

1

309

11

319

59.9%

0.09 [0.01, 0.71]

418 100.0%

0.25 [0.09, 0.67]

Total (95% CI)
Total events

417
6

Odds Ratio

M-H, Fixed, 95% CI

M-H, Fixed, 95% CI

Not estimable

18

Heterogeneity: Chi² = 2.03, df = 1 (P = 0.15); I² = 51%

0.01

Test for overall effect: Z = 2.74 (P = 0.006)

0.1

1

Dexamethasone

10

100

Prednisone/Predisolone

Figure 3a. Dexamethasone vs. Prednisone/Prednisolone, Outcome Vomiting in the ED (Gordon et al.,
2007)

Dexamethasone
Study or Subgroup

Events

Prednisone

Total Events

Odds Ratio

Total Weight

Altamini 2006

0

63

9

70

Gordon 2002

0

57

1

55

Qureshi 2001

6

272

11

261

Total (95% CI)
Total events

335
6

44.9%

0.05 [0.00, 0.89]

55.1%

0.51 [0.19, 1.41]

331 100.0%

0.31 [0.12, 0.75]

M-H, Fixed, 95% CI

Not estimable

20

Heterogeneity: Chi² = 2.51, df = 1 (P = 0.11); I² = 60%
Test for overall effect: Z = 2.60 (P = 0.009)

Odds Ratio

M-H, Fixed, 95% CI

0.01

0.1
Dexamethasone

1

10

100

Prednisone/Predisolone

Figure 4. Dexamethasone vs. Prednisone/Prednisolone, Outcome Vomiting at home. All studies except

Gordon et al., (2007) compare administration by mouth. Gordon et al., (2007) compared dexamethasone
intramuscularly vs. prednisone/prednisolone by mouth.
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Question 8: In the child hospitalized with an asthma exacerbation, should inhaled steroids
be initiated during an asthma exacerbation to improve pulmonary function or should inhaled
corticosteroids be continued if the treatment is included on the child’s home Asthma Action
Plan (AAP)?
Inpatient Asthma Team Recommendation:
We recommend starting or continuing an inhaled corticosteroid (ICS) in children hospitalized for an
asthma exacerbation. We do not recommend treating an asthma exacerbation with inhaled
corticosteroids ONLY. Doubling the AAP dose of ICS at the onset of an exacerbation is not
recommended. However, starting or continuing ICS for an inpatient with an asthma exacerbation
theoretically allows a foundation for assuring compliance with the AAP after discharge (Edmonds, Milan,
Brenner, Camargo, & Rowe, 2012; EPR-3, 2007; Rowe, Edmonds, Spooner, Diner, & Camargo, 2004),
although this has not been studied.
Literature supporting this recommendation:
EPR-3 (2007) makes the following statements:
Doubling the dose of the ICS does not appear to be effective (FitzGerald et al., 2004); Garrett,
Williams, Wong, & Holdaway, 1998; Harrison, Oborne, Newton, & Tattersfield, 2004). Multiple
high doses of an ICS (6 mg flunisolide over 3 hours) may be helpful in adults.
In children, the data is inconsistent (Rowe et al., 2004) most likely due to inconsistency in study
designs. A meta-analysis by (Edmonds et al., 2012)in a primarily adult population that compared ICS vs.
oral steroid and ICS, there was no significant difference in the odds ratio (OR) for asthma relapse at 710 days post treatment OR = 0.72, 95% CI [0.48, 1.1] and hospital admission OR = 0.99, 95% CI
[0.39, 2.52].
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Question 9: In the child hospitalized with an asthma exacerbation, should positive
expiratory pressure (PEP) therapy be used?
Inpatient Asthma team recommendation:
Based on very low quality evidence the Asthma Inpatient CPG team makes a weak recommendation that
PEP therapy may be used in the treatment of children hospitalized with asthma. Due to the lack of
evidence on this therapy, a strong quality project or research study should be done to understand the
efficacy of the treatment. Other alternatives may be equally reasonable. Further research (if performed)
is likely to have an important influence on our confidence in the estimate of the effect and is likely to
change the estimate.
Literature (Appendix E):
The literature was searched since the publication of EPR-3 (2007). Two studies were identified. The
studies are reported individually because the comparisons and outcomes differ for each study.
Christensen, Norregaard, Jensen, & Dahl 1993) compared β2-agonists and PEP with functional residual
capacity (FRC) and airway resistance (RAW). Frischknecht-Christensen, Norregaard, & Dahl (1991) used
the same comparison but measured peak expiratory flow (PEF) and forced expired volume (FEV). Neither
study showed improvement in the measured outcomes using PEP therapy. Clinical experience at
Children’s Mercy has shown the usefulness of PEP therapy in children with asthma. Texas Children’s
Hospital and Denver Children’s Hospital were contacted regarding the use of PEP therapy in hospitalized
children with asthma. Texas Children’s does not use PEP routinely and Denver Children’s uses EzPAP, not
PEP, due to the lack of evidence.

Forest Plot Comparisons
Study or Subgroup
Frischknecht-Christe 1991

Experimental-PEP
Control-Terbutaline
Mean Difference
Mean
SD Total Mean
SD Total Weight IV, Fixed, 95% CI
1.3 0.3588
8
1.1 0.1196
8 100.0% 0.20 [-0.06, 0.46]

Total (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.50 (P = 0.13)

8

Mean Difference
IV, Fixed, 95% CI

8 100.0% 0.20 [-0.06, 0.46]
-1
-0.5
0
0.5
1
Favours experimental Favours control

Figure 5. PEP versus Terbutaline, Outcome Symptom Score
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